The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002). Background: Immune checkpoint inhibitors (ICIs) relieve ...
Hosted on MSN
Systemic sclerosis research finds protein TLR8 influences the production of disease-related cytokines
Systemic sclerosis is an autoimmune disease that primarily causes inflammation of the skin, as well as internal organs such as the lungs and heart. It is considered a rare disease, and little is yet ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Multicenter, randomized, double-blinded, placebo-controlled trial of IFx-Hu2.0 (IFx) as adjunctive therapy with pembrolizumab (pembro) in checkpoint inhibitor (CPI)-naïve patients with advanced or ...
National Institute of Pharmaceutical R&D Co. Ltd. has identified Toll-like receptor 8 (TLR8) agonists reported to be useful for the treatment of cancer and viral infections.
Zhimeng Biopharma Inc. found a global partner for its hepatitis B virus (HBV) program, licensing rights to GSK plc for CB-06, an oral small-molecule Toll-like receptor 8 agonist. Pending positive data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback